As the industry seeks to reign in the high cost of drug development, one area with significant potential for cost savings is patient recruitment, typically responsible for about one-third of clinical trial costs.
Clinical study protocols are increasingly complex, and as a result, it now takes between 12 and 15 years for an investigational drug to go from lab to patient.³ Unfortunately, traditional recruitment methods—which rely primarily on direct-to-patient (DTP) marketing—are not keeping pace with demand, and researchers are unable to secure an adequate number of qualified participants on a timely basis. When recruitment goals are not met, trial delays ensue and costs increase.
Download Attachment
